Navigation Links
Refinement of glaucoma testing, treatment expected from US, United Kingdom study
Date:1/14/2010

An Indiana University School of Optometry researcher's ongoing work to improve testing for and treatment of one of the world's leading causes of blindness will advance with support from a $2.35 million grant from the National Institutes of Health.

IU School of Optometry Professor William H. Swanson will lead a research group that will conduct patient studies at optometry clinics in Bloomington, Indianapolis and New York City. Coupled with data from the United Kingdom, Swanson's team will work to improve methods for screening and testing for the presence, progression and pattern of damage due to glaucoma, a disease the National Eye Institute says affects 70 million people worldwide.

Swanson came to IU in 2006 from State University of New York State College of Optometry, where he remains an adjunct research professor. He holds a Ph.D. in biophysics and theoretical biology from the University of Chicago.

"Dr. Swanson's recruitment was made possible by the 2003 Commitment to Excellence (CTE) award to the School of Optometry," said Sarita Soni, Interim Dean of the School of Optometry.

The goals of the CTE proposal were to strengthen patient-based disease research at the School of Optometry, the school's Borish Center for Ophthalmic Research (BCOR) and IU Bloomington, and to better position the School of Optometry and the BCOR to compete for NIH-funded, patient-based research in ocular diseases and treatments.

"Dr. Swanson is precisely the type of faculty member we had in mind when the CTE proposal was developed," Soni added. "And I am grateful that IU Bloomington saw it fit to invest in the School of Optometry."

Swanson's research has already led to reconsideration of the widely held view that peripheral vision defects do not occur until after extensive loss of the ganglion cells. Ganglion cells transmit visual information from the retina to the brain.

Corroborated both independently and collaboratively by researchers in London, England, Swanson found widespread misinterpretation in comparisons of glaucoma patient data based on "inappropriate statistical analyses" that did not account for differences in units of measurement, lack of an independent variable and differences in dynamic range.

"This issue has now been raised by a number of laboratories and there is increasing awareness of the need to compensate for differences in linear versus logarithmic units," Swanson said of incorrect conclusions based on comparing structural (linear) and functional (logarithmic) measures in glaucoma patients.

Swanson's research path will now move toward optimizing and reducing variability in the perimetry testing that is used to find certain patterns of vision loss, especially early changes in vision caused by nerve damage from glaucoma. Regular perimetry tests are also used to monitor whether or not treatment for glaucoma is preventing further vision loss.

Perimetry, or visual field testing, measures central and peripheral vision, as a subject sits and looks inside a bowl-shaped instrument called a perimeter. The subject pushes a button each time a flash is seen while a computer notes the site of each flash and whether or not the subject pressed the button when the respective flash occurred. A resulting printout then displays areas of vision loss.

With a new quantitative model for creating statistical methods that accurately compare different clinical measures, along with development of a next generation of perimetry for glaucoma patients called contrast sensitivity perimetry (CSP), Swanson's work can focus on optimizing protocols for CSP testing in clinics, on testing the new model's predictions in a large database and on developing a better understanding of the relations between how glaucoma damage is measured by CSP and other clinical methods.

One hope researchers have is that close analysis of the data from a United Kingdom study group -- 450 glaucoma patients, some of whom have gone untreated -- could reduce both health care costs and side effects to patients associated with overtreatment. Data will also be gathered from 100 additional patients tested at optometry clinics in Bloomington, Indianapolis and New York City.

"This research will produce a deeper scientific understanding of perimetry and will lead to improved methods for using perimetry in clinical studies, treatment trials and care of individual patients," Swanson said. "The potential public health benefit is substantial, given the large number of patients with glaucoma."

Working with Swanson at Indiana University will be Dr. Victor Malinovsky, a clinical professor at the IU School of Optometry's Community Eye Care Center in Bloomington, Dr. Bradley Sutton, a clinical associate professor at the IU Indianapolis Eye Care Center, and Dr. Julie Torbit, a clinical assistant professor also at the IU Indianapolis Eye Care Center.

Collaborating with IU will be Dr. David Crabb at the Applied Vision Research Centre in the Department of Optometry and Visual Science at City University London, Dr. Mitchell Dul, director of the Glaucoma Institute at the SUNY State College of Optometry, and Drs. David Garway-Heath and Rizwan Malik, both of the Glaucoma Research Unit of Moorfields Eye Hospital in London.


'/>"/>

Contact: Steve Chaplin
stjchap@indiana.edu
812-856-1896
Indiana University
Source:Eurekalert

Related medicine news :

1. Scientists Report Refinements to Brain Surgery
2. Group Seeks Refinement of Knee Arthritis Treatment Guidelines
3. AUDIO from Medialink and Pfizer: Glaucoma - The Sneak Thief of Sight
4. Treating ROP in tiny preemies; better glaucoma follow-up in urban clinic
5. Toronto researchers discover novel circulation in human eye, new glaucoma treatment target
6. Glaucoma Tied to Gene Variants in Blacks
7. OcumatRx Announces Promising Clinical Trial Results for Implant with Potential to Permanently Treat Glaucoma
8. Quark Pharmaceuticals Announces Data Indicating Potential Utility of QPI-1007 for Treatment of Glaucoma
9. Medicare expenditures decrease for glaucoma surgery as number of procedures increases
10. Major Firms Eyeing CBMS Development of New Glaucoma Treatment
11. Transcend Medical Raises $35 Million Series B Round Towards Development of Novel Glaucoma Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2017)... ... 27, 2017 , ... From May 21-23, hearing healthcare professionals gained a competitive ... at the Marriott Syracuse Downtown Hotel in Syracuse, New York. , As EarQ’s ... hearing healthcare providers to help them stay ahead in the industry. At the event, ...
(Date:5/26/2017)... ... May 26, 2017 , ... Leading CEOs from biotech, ... 30th and 31st at The Four Seasons Hotel Boston. , The Boston ... sciences, offering exclusive access to key decision makers who influence deal making and ...
(Date:5/26/2017)... ... May 26, 2017 , ... A new analysis of ... the healthiest seniors are located in the Midwest. With the average cost of healthcare ... people are concerned with both the quality and affordability of where they live. An ...
(Date:5/26/2017)... ... ... After raising nearly $30,000 on Kickstarter , about three-times its original ... discounted crowdfunding price on Indiegogo . , “Along with creating an anti-stress gadget ... a fidget toy to the market that was made of superior quality and wouldn’t ...
(Date:5/26/2017)... ... May 26, 2017 , ... Dr. Alex Rabinovich, a highly-skilled ... a new, informational blog post on insurance options. If a Bay Area patient has ... help save time and money. Visiting an in-network provider for a second opinion can ...
Breaking Medicine News(10 mins):
(Date:5/22/2017)... N.Y. , May 22, 2017  Lilac ... treatment Gene-Eden-VIR/Novirin, announces the launch of a ... English, the results of a clinical study that ... year treatment with Gene-Eden-VIR/Novirin in individuals suffering from ... to note that there are no other treatments ...
(Date:5/15/2017)... , May 15, 2017  Amy Baxter MD, ... industry leader in noninvasive pain relief, was awarded a ... magazine. Baxter was recognized at the MM&M Top ... New York City on May 10, 2017. ... the biopharma industry go "beyond the pill."  ...
(Date:5/10/2017)... May 10, 2017 Hologic, Inc. (Nasdaq: ... for the fiscal second quarter ended April 1, 2017 ... $1.84 increased 666.7% compared to the prior year period ... in a significant gain, while non-GAAP diluted EPS of ... or 3.8% in constant currency terms.  Excluding the effects ...
Breaking Medicine Technology: